Department of Child and Adolescent Psychiatry, Psychosomatics, and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
tVNS Technologies GmbH, Erlangen, Germany.
Neuromodulation. 2023 Apr;26(3):507-517. doi: 10.1016/j.neurom.2022.07.007. Epub 2022 Aug 20.
Noninvasive transcutaneous vagus nerve stimulation (tVNS) has promising therapeutic potential in a wide range of applications across somatic and psychiatric conditions. Compared with invasive vagus nerve stimulation, good safety and tolerability profiles also support the use of tVNS in pediatric patients. Potential neurodevelopment-specific needs, however, raise concerns regarding the age-appropriate adjustment of treatment protocols and applied stimulation parameters.
In this study, we aimed to review registered trials and published studies to synthesize existing tVNS treatment protocols and stimulation parameters applied in pediatric patients.
A systematic search of electronic data bases (PubMed, Scopus, MEDLINE, Cochrane Library, and PsycINFO) and ClinicalTrials was conducted. Information on patient and study-level characteristics (eg, clinical condition, sample size), the tVNS device (eg, brand name, manufacturer), stimulation settings (eg, pulse width, stimulation intensity), and stimulation protocol (eg, duration, dosage of stimulation) was extracted.
We identified a total of 15 publications (four study protocols) and 15 registered trials applying tVNS in pediatric patients (<18 years of age). Most of these studies did not exclusively address pediatric patients. None of the studies elaborated on neurodevelopmental aspects or justified the applied protocol or stimulation parameters for use in pediatric patients.
No dedicated pediatric tVNS devices exist. Neither stimulation parameters nor stimulation protocols for tVNS are properly justified in pediatric patients. Evidence on age-dependent stimulation effects of tVNS under a neurodevelopment framework is warranted. We discuss the potential implications of these findings with clinical relevance, address some of the challenges of tVNS research in pediatric populations, and point out key aspects in future device development and research in addition to clinical studies on pediatric populations.
非侵入性经皮迷走神经刺激(tVNS)在躯体和精神疾病的广泛应用中具有有前景的治疗潜力。与侵入性迷走神经刺激相比,良好的安全性和耐受性也支持 tVNS 在儿科患者中的应用。然而,潜在的神经发育特定需求引起了对治疗方案和应用刺激参数进行适当年龄调整的关注。
本研究旨在综述已注册的试验和已发表的研究,以综合现有的 tVNS 治疗方案和应用于儿科患者的刺激参数。
系统地检索电子数据库(PubMed、Scopus、MEDLINE、Cochrane 图书馆和 PsycINFO)和 ClinicalTrials,提取关于患者和研究水平特征(例如临床状况、样本量)、tVNS 设备(例如,品牌名称、制造商)、刺激设置(例如,脉冲宽度、刺激强度)和刺激方案(例如,持续时间、刺激剂量)的信息。
我们共确定了 15 篇文献(4 篇研究方案)和 15 项已注册的儿科患者应用 tVNS 的试验。这些研究中大多数并没有专门针对儿科患者。没有研究详细阐述了神经发育方面的内容,也没有为儿科患者应用的方案或刺激参数提供合理性依据。
没有专门的儿科 tVNS 设备。tVNS 的刺激参数和刺激方案在儿科患者中都没有得到适当的论证。有必要根据神经发育框架研究 tVNS 的年龄依赖性刺激效应。我们讨论了这些发现的潜在临床意义,涉及儿科人群中 tVNS 研究的一些挑战,并指出了在儿科人群的临床研究之外,在未来设备开发和研究中的关键方面。